Success Metrics

Clinical Success Rate
44.4%

Based on 4 completed trials

Completion Rate
44%(4/9)
Active Trials
0(0%)
Results Posted
200%(8 trials)
Terminated
5(56%)

Phase Distribution

Ph phase_1
7
78%
Ph phase_2
2
22%

Phase Distribution

7

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
7(77.8%)
Phase 2Efficacy & side effects
2(22.2%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

44.4%

4 of 9 finished

Non-Completion Rate

55.6%

5 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(4)
Terminated(5)

Detailed Status

Terminated5
Completed4

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
44.4%
Most Advanced
Phase 2

Trials by Phase

Phase 17 (77.8%)
Phase 22 (22.2%)

Trials by Status

completed444%
terminated556%

Recent Activity

0 active trials
Showing 5 of 9
terminatedphase_1

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

NCT04789668
terminatedphase_1

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

NCT01378377
completedphase_2

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

NCT01693068
terminatedphase_1

A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy

NCT01668017
terminatedphase_2

Trial of Pimasertib in Hematological Malignancies

NCT00957580
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04789668Phase 1

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Terminated
NCT01378377Phase 1

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

Terminated
NCT01693068Phase 2

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Completed
NCT01668017Phase 1

A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy

Terminated
NCT00957580Phase 2

Trial of Pimasertib in Hematological Malignancies

Terminated
NCT01713036Phase 1

Oral Bioavailability and Mass Balance Trial With Pimasertib

Completed
NCT01016483Phase 1

Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer

Completed
NCT01085331Phase 1

MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)

Terminated
NCT01985191Phase 1

A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9